Vimarsana
Biggest News Aggregation in the World

Page 2 - Area Lead News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Area Lead. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Area Lead Today - Breaking & Trending Today

Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations - Vimarsana News

Johnson & Johnson : receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations

Media contact: Investor contact: ...

Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC - Vimarsana News

Frontline Amivantamab Plus Chemo Receives Positive EU CHMP Opinion for EGFR Exon 20 Insertion+ NSCLC

Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.

European Commission Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma - Vimarsana News

European Commission Approves Cilta-Cel for Relapsed/Refractory Multiple Myeloma

Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.

Janssen's antibody drug shows phase 2 potential in rheumatoid arthritis - Vimarsana News

Janssen's antibody drug shows phase 2 potential in rheumatoid arthritis

The proof-of-concept trial, dubbed IRIS-RA, is the first to investigate a treatment for rheumatoid arthritis that blocks a protein called neonatal Fc receptor (FcRn). The antibody drug nipocalimab, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, has shown early promise for treating rheumatoid arthritis (RA) in a phase 2a trial.

S. KOREAN AUTOMATION INNOVATOR PARTNERS WITH DISHER TO BRING SECOND GEN-AMR TO THE U.S. - Vimarsana News

S. KOREAN AUTOMATION INNOVATOR PARTNERS WITH DISHER TO BRING SECOND GEN-AMR TO THE U.S.

/PRNewswire/ -- THIRA ROBOTICS—the AMR subsidiary of THiRA-UTECH—signed a MOU with U.S.-based solution engineering innovator and system integrator, DISHER. The...